As shown in Table 1, high 53BP1 expressers assessed by IHC exhibited significantly higher mitotic activity (p = 0.016) and increased proportions of cases classified into higher risk levels by both the NIH risk scheme and the NCCN guidelines (both p ≤ 0.001), but they showed no association with tumor size or location. This evidence concerns the gene TP53BP1 and neoplasm.